Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check3 days agoChange DetectedAdded a Locations section with Texas as the study site. The page revision updated to v3.3.3.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed, a minor metadata update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedThe funding-status notice banner was removed. The page previously warned that information may be out of date due to a lapse in government funding.SummaryDifference0.4%

- Check54 days agoChange DetectedOnly minor administrative updates are visible on the page, including the latest update date and minor layout tweaks. The core study details—eligibility criteria, enrollment numbers, study design, and primary/secondary outcomes—appear unchanged.SummaryDifference0.4%

- Check83 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

- Check90 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.